1-5 of 5
Johan L. Nielsen, MD
Close
Sort by
Journal Articles

A Prospective Study of Imatinib 400 mg vs 800 mg Frontline in High Risk Ph+ Chronic Myeloid Leukemia (CML) Patients.

Michele Baccarani, MD, Fausto Castagnetti, MD, Kimmo Porkka, MD, Johan L. Nielsen, MD, Henrik Hjorth-Hansen, MD, Ibrahim Haznedaroglu, MD, Arnon Nagler, MD, Giovanna Rege-Cambrin, MD, Giorgina Specchia, MD, Marilina Amabile, BD, Nicoletta Testoni, BD, Francesca Palandri, MD, Fabrizio Pane, MD, Giuliana Alimena, MD, Giovanni Martinelli, MD, Gianantonio Rosti, MD, Bengt Simonsson, MD
Journal: Blood
Blood (2007) 110 (11): 26.
https://doi.org/10.1182/blood.V110.11.26.26
Published: 2007
Journal Articles

Expression Pattern and Prognostic Impact of Vascular Endothelial Growth Factors VEGF and VEGF-C and Their Receptors Flt-1, KDR and Flt-4 in Peripheral T-Cell Lymphomas.

Judit M. Jørgensen, MD, PhD, Flemming B. Sørensen, MD, D.M.Sci., Knud Bendix, MD., D.M.Sci., Johan L. Nielsen, MD., D.M.Sci., Anette D. Funder, Tapio Tainola, Marika Karkkainen, Ph.D., Annette B. Sørensen, M.Sci, Ph.D., Finn S. Pedersen, M.Sci, Astrid V. Kühle, Francesco d’Amore, MD., D.M.Sci.
Journal: Blood
Blood (2007) 110 (11): 689.
https://doi.org/10.1182/blood.V110.11.689.689
Published: 2007
Journal Articles

Imatinib High Dose (800 mg): Results of a Phase II Trial of the GIMEMA (Gruppo Italiano Malattie Ematologiche Dell’Adulto) CML Working Party in Intermediate Sokal Risk Patients and Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients.

Gianantonio Rosti, MD, Fausto Castagnetti, MD, Marilina Amabile, BD, Nicoletta Testoni, BD, Angela Poerio, BD, Giulia Marzocchi, BD, Massimo Breccia, MD, Francesca Palandri, MD, Tamara Intermesoli, MD, Fabio Stagno, MD, Giorgina Specchia, MD, Elisabetta Abruzzese, MD, Panagiota Giannoulia, MD, Giuseppe Saglio, MD, Fabrizio Pane, MD, Francesca Rancati, BD, Arnon Nagler, MD, Ibrahim Haznedaroglu, MD, Kimmo PorkKa, MD, Henrik Hjorth-Hansen, MD, Johan L. Nielsen, MD, Bengt Simonsson, MD, Giovanni Martinelli, MD, Michele Baccarani, MD
Journal: Blood
Blood (2006) 108 (11): 4776.
https://doi.org/10.1182/blood.V108.11.4776.4776
Published: 2006
Journal Articles

Expression Level, Tissue Distribution Pattern and Prognostic Impact of Vascular Endothelial Growth Factor (VEGF) and Its Receptors Flt-1 and KDR in Different Subtypes of Non-Hodgkin Lymphoma (NHL).

Judit M. Jørgensen, MD, Flemming B. Sørensen, MD, DMSci., Knud Bendix, MD, DMSci, Johan L. Nielsen, MD, DMSci., Anette Funder, Tapio Tainola, Annette B. Sørensen, PhD, Francesco d’Amore, MD, DMSci.
Journal: Blood
Blood (2005) 106 (11): 2824.
https://doi.org/10.1182/blood.V106.11.2824.2824
Published: 2005
Journal Articles

Imatinib 800 mg: Preliminary Results of a Phase II Trial of the GIMEMA CML Working Party in Intermediate Sokal Risk Patients and Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients.

Gianantonio Rosti, MD, Giovanni Martinelli, MD, Fausto Castagnetti, MD, Nicoletta Testoni, BD, Giorgina Specchia, MD, Renato Bassan, MD, Fabio Stagno, MD, Massimo Breccia, MD, Elisabetta Abruzzese, MD, Giuseppe Saglio, MD, Fabrizio Pane, MD, Bengt Simonsson, MD, Johan L. Nielsen, MD, Henrik Hjorth-Hansen, MD, Kimmo PorkKa, MD, Ibrahim Haznedaroglu, MD, Arnon Nagler, MD, Marco Vignetti, MD, Domenico Russo, MD, Marilina Amabile, BD, Michele Baccarani, MD
Journal: Blood
Blood (2005) 106 (11): 1098.
https://doi.org/10.1182/blood.V106.11.1098.1098
Published: 2005